126 related articles for article (PubMed ID: 26339343)
1. Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.
Fu J; Luo B; Guo WW; Zhang QM; Shi L; Hu QP; Chen F; Xiao SW; Xie XX
Int J Clin Exp Pathol; 2015; 8(7):7786-97. PubMed ID: 26339343
[TBL] [Abstract][Full Text] [Related]
2. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma.
Luo B; Yun X; Li J; Fan R; Guo WW; Liu C; Lin YD; Ge YY; Zeng X; Bi SQ; Nong WX; Zhang QM; Xie XX
Curr Med Sci; 2020 Aug; 40(4):719-728. PubMed ID: 32862383
[TBL] [Abstract][Full Text] [Related]
3. OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG, CD9, CCND2 and CDCA3: a bioinformatic analysis combine with RNAi and oligonucleotide microarray.
Hu Q; Fu J; Luo B; Huang M; Guo W; Lin Y; Xie X; Xiao S
Oncol Rep; 2015 Apr; 33(4):1965-75. PubMed ID: 25673160
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells.
Cen YH; Guo WW; Luo B; Lin YD; Zhang QM; Zhou SF; Luo GR; Xiao SW; Xie XX
Cell Biol Int; 2012 Oct; 36(10):917-22. PubMed ID: 22651134
[TBL] [Abstract][Full Text] [Related]
5. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
Wang Z; Wei W; Sun CK; Chua MS; So S
Liver Int; 2015 Apr; 35(4):1403-15. PubMed ID: 25098386
[TBL] [Abstract][Full Text] [Related]
6. Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Huang XQ; Zhang XF; Xia JH; Chao J; Pan QZ; Zhao JJ; Zhou ZQ; Chen CL; Tang Y; Weng DS; Zhang JH; Xia JC
Chin J Cancer; 2017 Sep; 36(1):77. PubMed ID: 28950898
[TBL] [Abstract][Full Text] [Related]
7. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
Kim JK; Jung KH; Noh JH; Eun JW; Bae HJ; Xie HJ; Ahn YM; Ryu JC; Park WS; Lee JY; Nam SW
Int J Oncol; 2009 Dec; 35(6):1257-64. PubMed ID: 19885547
[TBL] [Abstract][Full Text] [Related]
8. RBP-J-interacting and tubulin-associated protein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma by activating the p53-Fbxw7 pathway.
Wang H; Yang Z; Liu C; Huang S; Wang H; Chen Y; Chen G
Biochem Biophys Res Commun; 2014 Nov; 454(1):71-7. PubMed ID: 25445601
[TBL] [Abstract][Full Text] [Related]
9. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2].
Xu JY; Chen LB; Xu JY; Yang Z; Wei HY; Xu RH
Ai Zheng; 2006 May; 25(5):526-32. PubMed ID: 16687068
[TBL] [Abstract][Full Text] [Related]
11. Calreticulin down-regulation inhibits the cell growth, invasion and cell cycle progression of human hepatocellular carcinoma cells.
Feng R; Ye J; Zhou C; Qi L; Fu Z; Yan B; Liang Z; Li R; Zhai W
Diagn Pathol; 2015 Aug; 10():149. PubMed ID: 26307067
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
[TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells.
Cho SB; Park YL; Song YA; Kim KY; Lee GH; Cho DH; Myung DS; Park KJ; Lee WS; Chung IJ; Choi SK; Kim KK; Joo YE
Oncol Rep; 2011 Dec; 26(6):1581-6. PubMed ID: 21874262
[TBL] [Abstract][Full Text] [Related]
14. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.
Ono T; Kurashige T; Harada N; Noguchi Y; Saika T; Niikawa N; Aoe M; Nakamura S; Higashi T; Hiraki A; Wada H; Kumon H; Old LJ; Nakayama E
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3282-7. PubMed ID: 11248070
[TBL] [Abstract][Full Text] [Related]
15. RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma.
Deng Q; Li KY; Chen H; Dai JH; Zhai YY; Wang Q; Li N; Wang YP; Han ZG
Hepatology; 2014 Feb; 59(2):518-30. PubMed ID: 23929653
[TBL] [Abstract][Full Text] [Related]
16. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
17. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of G protein-coupled receptor 137 by RNA interference inhibits cell growth of two hepatoma cell lines.
Shao X; Liu Y; Huang H; Zhuang L; Luo T; Huang H; Ge X
Cell Biol Int; 2015 Apr; 39(4):418-26. PubMed ID: 25490967
[TBL] [Abstract][Full Text] [Related]
19. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
20. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.
Tammela J; Uenaka A; Ono T; Noguchi Y; Jungbluth AA; Mhawech-Fauceglia P; Qian F; Schneider S; Sharma S; Driscoll D; Lele S; Old LJ; Nakayama E; Odunsi K
Int J Oncol; 2006 Oct; 29(4):903-10. PubMed ID: 16964386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
